[
  {
    "headline": "pharmaceutical q1 review jazz pharmaceutical nasdaq jazz vs peer",
    "text": "q1 earning season wrap let dig quarter good bad performer pharmaceutical industry include jazz pharmaceutical nasdaq jazz peer"
  },
  {
    "headline": "theravance q1 loss wide expect revenue rise",
    "text": "tbph report weak expect first quarter 2025 result collaboration revenue viatris rise year year"
  },
  {
    "headline": "viatris inc vtrs q1 2025 earning call highlight navigating challenge capitalize",
    "text": "despite revenue dip goodwill impairment viatris inc vtrs focus strategic growth shareholder return promise new product development"
  },
  {
    "headline": "q1 2025 viatris inc earning call",
    "text": "q1 2025 viatris inc earning call"
  },
  {
    "headline": "viatris q1 earning revenue beat estimate gain",
    "text": "vtrs q1 earning sale beat estimate brand business continue perform well back expansion"
  },
  {
    "headline": "viatris nasdaq vtrs report sale analyst estimate q1 earning soar 8",
    "text": "medication company viatris nasdaq vtrs fall short revenue expectation q1 cy2025 sale fall 11.2 year year $ 3.25 billion company full year revenue guidance $ 13.75 billion midpoint come 0.5 analyst estimate non gaap profit $ 0.50 per line analyst consensus estimate"
  },
  {
    "headline": "viatris vtrs report q1 earning key metric say",
    "text": "top- bottom line number viatris vtrs give sense business perform quarter end march 2025 could worth look key metric compare wall street estimate year ago value"
  },
  {
    "headline": "viatris vtrs beat q1 earning revenue estimate",
    "text": "viatris vtrs deliver earning revenue surprise 2.04 0.81 respectively quarter end march 2025 number hold clue lie ahead"
  },
  {
    "headline": "viatris q1 earning snapshot",
    "text": "canonsburg pa ap viatris inc vtrs thursday report loss $ 3.04 billion first quarter per basis canonsburg pennsylvania base company say loss $ 2.55"
  },
  {
    "headline": "viatris report first quarter 2025 result reaffirm 2025 outlook",
    "text": "viatris inc nasdaq vtrs today report first quarter 2025 result reaffirm 2025 outlook 1"
  },
  {
    "headline": "viatris announce positive result phase 3 study investigational xulane lo low dose patch birth control woman childbeare potential",
    "text": "viatris inc nasdaq vtrs global healthcare company today announce positive result phase 3 study nct05139121 evaluate contraceptive efficacy safety investigational xulane lo low dose weekly dermal patch 150 mcg norelgestromin 17.5 mcg ethinyl estradiol per day woman childbeare potential study evaluate woman childbeare potential n 1,272 13 cycle 12,591 safety evaluable cycle 9,105 efficacy evaluable cycle across 81 inve"
  },
  {
    "headline": "viatris announce positive top line result two pivotal phase 3 study novel fast act meloxicam mr-107a-02 treatment moderate severe acute pain",
    "text": "viatris inc nasdaq vtrs global healthcare company today announce positive result phase 3 program novel fast act formulation meloxicam mr-107a-02 treatment moderate severe acute pain phase 3 program consist two randomize double blind placebo-(double dummy active control trial one follow herniorrhaphy surgery nct06215859 one follow bunionectomy surgery nct06215820 trial evaluate efficacy safety"
  },
  {
    "headline": "viatris announce quarterly dividend",
    "text": "viatris inc nasdaq vtrs today announce may 5 2025 board director declare quarterly dividend $ 0.12 per issue outstanding company common dividend payable june 16 2025 shareholder record close business may 23 2025"
  },
  {
    "headline": "viatris earning look vtrs",
    "text": "medication company viatris nasdaq vtrs report result tomorrow morning need know"
  },
  {
    "headline": "sector update health care fall late afternoon",
    "text": "health care decline late tuesday afternoon nyse health care fall 2.6"
  },
  {
    "headline": "viatris announce appointment frank amelio michael severino m.d company board director",
    "text": "viatris inc nasdaq vtrs global healthcare company today announce part ongoing board refreshment effort frank amelio michael severino m.d appoint new member viatris board director addition company announce current director rajiv malik harry hal korman retire board end current term december follow company 2025 annual meeting shareholder"
  },
  {
    "headline": "unveiling viatris vtrs q1 outlook wall street estimate key metric",
    "text": "get deep insight potential performance viatris vtrs quarter end march 2025 go beyond wall street top -and bottom line estimate examine estimate key metric"
  },
  {
    "headline": "2 p 500 worth investigate 1 avoid",
    "text": "p 500 gspc home big well know company make go seek stability large cap create equal struggle slow growth decline margin increase competition"
  },
  {
    "headline": "viatris q1 earning release store",
    "text": "vtrs q1 result likely gain new product launch major geography"
  },
  {
    "headline": "analyst estimate viatris vtrs report decline earning look",
    "text": "viatris vtrs possess right combination two key ingredient likely earning beat upcoming report get prepare key expectation"
  },
  {
    "headline": "pharmaceutical q1 review jazz pharmaceutical nasdaq jazz vs peer",
    "text": "q1 earning season wrap let dig quarter good bad performer pharmaceutical industry include jazz pharmaceutical nasdaq jazz peer"
  },
  {
    "headline": "theravance q1 loss wide expect revenue rise",
    "text": "tbph report weak expect first quarter 2025 result collaboration revenue viatris rise year year"
  },
  {
    "headline": "viatris inc vtrs q1 2025 earning call highlight navigating challenge capitalize",
    "text": "despite revenue dip goodwill impairment viatris inc vtrs focus strategic growth shareholder return promise new product development"
  },
  {
    "headline": "q1 2025 viatris inc earning call",
    "text": "q1 2025 viatris inc earning call"
  },
  {
    "headline": "viatris q1 earning revenue beat estimate gain",
    "text": "vtrs q1 earning sale beat estimate brand business continue perform well back expansion"
  },
  {
    "headline": "viatris nasdaq vtrs report sale analyst estimate q1 earning soar 8",
    "text": "medication company viatris nasdaq vtrs fall short revenue expectation q1 cy2025 sale fall 11.2 year year $ 3.25 billion company full year revenue guidance $ 13.75 billion midpoint come 0.5 analyst estimate non gaap profit $ 0.50 per line analyst consensus estimate"
  },
  {
    "headline": "viatris vtrs report q1 earning key metric say",
    "text": "top- bottom line number viatris vtrs give sense business perform quarter end march 2025 could worth look key metric compare wall street estimate year ago value"
  },
  {
    "headline": "viatris vtrs beat q1 earning revenue estimate",
    "text": "viatris vtrs deliver earning revenue surprise 2.04 0.81 respectively quarter end march 2025 number hold clue lie ahead"
  },
  {
    "headline": "viatris q1 earning snapshot",
    "text": "canonsburg pa ap viatris inc vtrs thursday report loss $ 3.04 billion first quarter per basis canonsburg pennsylvania base company say loss $ 2.55"
  },
  {
    "headline": "viatris report first quarter 2025 result reaffirm 2025 outlook",
    "text": "viatris inc nasdaq vtrs today report first quarter 2025 result reaffirm 2025 outlook 1"
  },
  {
    "headline": "viatris announce positive result phase 3 study investigational xulane lo low dose patch birth control woman childbeare potential",
    "text": "viatris inc nasdaq vtrs global healthcare company today announce positive result phase 3 study nct05139121 evaluate contraceptive efficacy safety investigational xulane lo low dose weekly dermal patch 150 mcg norelgestromin 17.5 mcg ethinyl estradiol per day woman childbeare potential study evaluate woman childbeare potential n 1,272 13 cycle 12,591 safety evaluable cycle 9,105 efficacy evaluable cycle across 81 inve"
  },
  {
    "headline": "viatris announce positive top line result two pivotal phase 3 study novel fast act meloxicam mr-107a-02 treatment moderate severe acute pain",
    "text": "viatris inc nasdaq vtrs global healthcare company today announce positive result phase 3 program novel fast act formulation meloxicam mr-107a-02 treatment moderate severe acute pain phase 3 program consist two randomize double blind placebo-(double dummy active control trial one follow herniorrhaphy surgery nct06215859 one follow bunionectomy surgery nct06215820 trial evaluate efficacy safety"
  },
  {
    "headline": "viatris announce quarterly dividend",
    "text": "viatris inc nasdaq vtrs today announce may 5 2025 board director declare quarterly dividend $ 0.12 per issue outstanding company common dividend payable june 16 2025 shareholder record close business may 23 2025"
  },
  {
    "headline": "viatris earning look vtrs",
    "text": "medication company viatris nasdaq vtrs report result tomorrow morning need know"
  },
  {
    "headline": "sector update health care fall late afternoon",
    "text": "health care decline late tuesday afternoon nyse health care fall 2.6"
  },
  {
    "headline": "viatris announce appointment frank amelio michael severino m.d company board director",
    "text": "viatris inc nasdaq vtrs global healthcare company today announce part ongoing board refreshment effort frank amelio michael severino m.d appoint new member viatris board director addition company announce current director rajiv malik harry hal korman retire board end current term december follow company 2025 annual meeting shareholder"
  },
  {
    "headline": "unveiling viatris vtrs q1 outlook wall street estimate key metric",
    "text": "get deep insight potential performance viatris vtrs quarter end march 2025 go beyond wall street top -and bottom line estimate examine estimate key metric"
  },
  {
    "headline": "2 p 500 worth investigate 1 avoid",
    "text": "p 500 gspc home big well know company make go seek stability large cap create equal struggle slow growth decline margin increase competition"
  },
  {
    "headline": "viatris q1 earning release store",
    "text": "vtrs q1 result likely gain new product launch major geography"
  },
  {
    "headline": "analyst estimate viatris vtrs report decline earning look",
    "text": "viatris vtrs possess right combination two key ingredient likely earning beat upcoming report get prepare key expectation"
  },
  {
    "headline": "viatris inc vtrs among bad perform p 500 far 2025",
    "text": "recently publish list 11 bad perform p 500 far 2025 article take look viatris inc nasdaq vtrs stand bad perform year two year surge 53 mark good performance broad since"
  },
  {
    "headline": "viatris inc vtrs one cheap quarterly dividend buy",
    "text": "recently publish list 10 cheap quarterly dividend buy article go take look viatris inc nasdaq vtrs stand overlook dividend current environment look seek stable income way protect"
  },
  {
    "headline": "generic pharmaceutical q4 teardown viatris nasdaq vtrs vs rest",
    "text": "let dig relative performance viatris nasdaq vtrs peer unravel complete q4 generic pharmaceutical earning season"
  },
  {
    "headline": "viatris inc vtrs among billionaire ken fisher healthcare pick massive upside potential",
    "text": "recently publish list billionaire ken fisher 10 healthcare pick massive upside potential article go take look viatris inc nasdaq vtrs stand billionaire ken fisher healthcare pick massive upside potential healthcare industry essential component global well"
  },
  {
    "headline": "viatris present bofa security 2025 healthcare conference",
    "text": "viatris inc nasdaq vtrs global healthcare company present bofa security 2025 healthcare conference las vegas nv tuesday may 13 2025 company presentation begin 5 p.m. pt 8 p.m. et"
  },
  {
    "headline": "3 reason vtrs risky 1 buy instead",
    "text": "viatris take beating past six month shed 33 value fall $ 7.69 per partly due soft quarterly result might contemplate next move"
  },
  {
    "headline": "viatris inc nasdaq vtrs well cheap buy $ 10",
    "text": "recently publish list 10 well cheap buy $ 10 article go take look viatris inc nasdaq vtrs stand cheap buy $ 10 april 21 tom lee fundstrat cio co founder managing partner join squawk box cnbc"
  },
  {
    "headline": "viatris file supplemental new drug application japan ministry health labor welfare approval effexor treatment generalized anxiety disorder",
    "text": "viatris inc nasdaq vtrs global healthcare company today announce file application ministry health labor welfare mhlw approval effexor sr capsule venlafaxine hydrochloride serotonin noradrenaline reuptake inhibitor snri treat adult generalized anxiety disorder gad indication treatment option currently approve japan"
  },
  {
    "headline": "pharmaceutical q4 review jazz pharmaceutical nasdaq jazz vs peer",
    "text": "earning result often indicate direction company take month ahead q4 behind let look jazz pharmaceutical nasdaq jazz peer"
  },
  {
    "headline": "viatris inc vtrs top healthcare buy accord billionaire david einhorn",
    "text": "recently publish list top 9 healthcare buy accord billionaire david einhorn article go take look viatris inc nasdaq vtrs stand top healthcare buy accord billionaire david einhorn wall street come crash president donald trump"
  },
  {
    "headline": "viatris appoint hemanth j. varghese chief strategy officer",
    "text": "viatris inc nasdaq vtrs today announce hemanth j. varghese join company chief strategy officer varghese member company executive leadership team"
  },
  {
    "headline": "viatris inc vtrs among high dividend invest $ 10",
    "text": "recently publish list 13 high dividend invest $ 10 article go take look viatris inc nasdaq vtrs stand high dividend $ 10 often favor dividend long term potential appeal stem consistent growth"
  },
  {
    "headline": "3 hate mount challenge",
    "text": "rock bottom always mean rock bottom business examine today touch 52 week low create classic dilemma bargain opportunity value trap"
  },
  {
    "headline": "3 beat trade book value",
    "text": "company book value equal total asset less liability book value consider future deal otherwise solid company book value per bvps"
  },
  {
    "headline": "viatris pay $ 335 million settlement opioid relate claim",
    "text": "vtrs reach agreement $ 335 million resolve opioid relate claim state local government tribe certain subsidiary"
  }
]